Tocilizumab in COVID-19: A Double-Edged Sword?
Author Information
Author(s): Kudliński Bartosz, Zawadzki Jacek, Kulińska Wiktoria, Kania Jagoda, Murkos Magdalena, Stolińska Marta, Zgoła Dominika, Noga Anna, Nowak Paweł, Romaniuk-Drapała Aleksandra
Primary Institution: Department of Anesthesia, Critical Care and Rescue Medicine, Collegium Medicum, University in Zielona Góra, Poland
Hypothesis
The combined therapy with tocilizumab and steroids in adequate doses aimed at suppressing the cytokine storm in severe COVID-19-related ARDS is associated with improved prognosis among patients undergoing intensive care.
Conclusion
Tocilizumab was found to be both efficient and safe despite the increased risk of positive results for secondary infections.
Supporting Evidence
- The highest survival rate was observed among patients under 61 years old receiving combined treatment.
- Atrial fibrillation and coronary heart disease correlated with lower survival rates.
- Tocilizumab was associated with an increased risk of positive pathogen cultures but higher survival rates.
- Mechanical ventilation and ICU procedures significantly decreased mortality rates.
Takeaway
Tocilizumab is a medicine that helps people with severe COVID-19 by reducing inflammation, but it can also increase the risk of infections. However, it doesn't seem to make patients die more often.
Methodology
This study included 342 patients qualified for the ICU and mechanical ventilation, divided based on the type of immunomodulating therapy and culture test results.
Potential Biases
Potential confounding factors and selection bias may influence the results.
Limitations
The study is limited by its single-center design and the exclusion of 25 patients due to incomplete data.
Participant Demographics
All patients were unvaccinated adults admitted to the ICU with severe COVID-19-related ARDS.
Statistical Information
P-Value
0.051
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website